CClinicalTrials.gg
CompletedNCT04363138ELISAUpdated Jan 12, 2023

Link Between Eosinopenia and Bacterial Infections in the Elderly Subject Hospitalized in Geriatrics

An observational study in Fever, Leukocytes and C Reactive Protein (CRP) is Less Than 20 mg/ l, sponsored by Gérond'if. Completed at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2023-01-12.

Sponsored by Gérond'if · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
156
Ages
75 Years and older
Sex
All
01

Study summary

The main purpose of this monocentric, non-interventional, prospective study carried out in acute geriatrics (UGA) and post-rehabilitation care, is to determine if eosinopenia is associated with bacterial infections.

Read the detailed description

It's a monocentric, non-interventional, prospective study carried.

At inclusion:

Non-opposition will be collected by the investigator upon entering the Geriatric Unit.

The investigators will have all the biological and radiological results and will decide whether or not to start antibiotic treatment.

Patients will be divided into 2 groups: group with bacterial infections and the other with non-bacterial diseases.

The patient's socio-demographic data, reason for hospitalization, history, BMI, state of dependence (ADL-IADL), MMSE, treatments will be collected. Biological examinations in the phase where an infection is not suspected will also be collected (NFS, ionogram, urea, creatinemia, albumin, pre albumin, CRP, hepatocellular workup. Clinical examination during the episode may be infectious as well that biological and radiological data will be collected as well as the diagnosis made.

Antibiotic treatment is prescribed will be listed. The blood levels of eosinophils between the two groups will be compared.

Follow-up at 1 month:

The effectiveness of antibiotics will be evaluated on the absence of inflammatory syndrome and fever after the recommended antibiotic treatment and the duration of the recommended treatment. Vital status will be collected.

02

Conditions studied

  • Fever
  • Leukocytes
  • C Reactive Protein (CRP) is Less Than 20 mg/ l

Keywords

  • Eosinopenia
  • Bacterial infections
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 156 is below the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Gérond'if is the lead sponsor of 35 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects above 75 years of age, hospitalized in geriatrics.

Inclusion criteria

  • Hospitalized in Geriatrics.
  • First episode of:
  • Fever> 38 ° motivating the realization of a biological assessment.
  • Or Leukocytes> 10 g / l and C reactive protein (CRP) > 20 mg / l.
  • Be affiliated to a social security scheme.
  • No oral opposition to participation in the study and use of the data.

Exclusion criteria

Exclusion Criteria:

  • Immunosuppression (HIV with CD4 \<200 / mm3)
  • Active corticosteroid therapy
  • Asthma
  • Chemotherapy, immunosuppressive treatment
  • Malignant hematological disease, lympho or myeloproliferative syndrome
  • Antibiotic therapy initiated before entering the geriatric ward
  • Documented parasitosis
  • Eosinophilic vasculitis
  • stroke \<30 days
  • Patient already included in another study
  • Patient under guardianship or curatorship
  • Not affiliated with a social security scheme
  • Oral opposition to participation in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
156 participants (actual)
Patient registry
No

Groups and cohorts

  • bacterial infection

    Patients with bacterial infection

  • No bacterial infection

    Patients without bacterial infection

06

What researchers measure

Primary outcomes

  1. Determine if eosinopenia is associated with bacterial infections by measuring eosinophil counts.

    Time frame: 1 month

Secondary outcomes

  1. Determine if eosinopenia is associated with the effectiveness of antibiotics by measuring eosinophil counts.

    Time frame: 1 month

  2. Determine if the eosinophil counts (PNE) / neutrophil (PNN)x1000 < 4 ratio is associated with a bacterial infection by measuring this value.

    Time frame: 1 month

  3. Determine if eosinopenia is associated with mortality by measuring eosinophil counts.

    Time frame: 1 month

  4. Determine if deep eosinopenia is associated with bacterial involvement by measuring if this value is less than 10 per mm3.

    Time frame: 1 month.

07

Study locations

1 site
  • Geriatric Department, Paul Brousse Hospital
    Villejuif, Ile-de-France 94800, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04363138
Lead sponsor
Gérond'if
Responsible party
Sponsor
First posted
Apr 27, 2020
Start date
Jul 2, 2021
Primary completion
Aug 1, 2021
Completion
Aug 1, 2022
Last update
Jan 12, 2023

Study contacts

Emmanuelle DURON, MD PhD
study chair · Geriatric Department, Paul Brousse Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion